Digging into Biohaven's BHV-0223 in treating ALSTicker(s): BHVN, CTLT
A neurologist with experience treating ALS, and knowledge of BHV-0223 and its sublingual delivery method developed in collaboration with Catalent's Zydis ODT fast-dissolve technology.
Please tell us about your clinical experience. How many patients do you currently treat with ALS?Added By: slingshot_insights
How do you prevent progression of the disease? What are the pros and cons of using riluzole or edaravone?Added By: slingshot_insights
How much of a need is there for a Sublingual Delivery Form for riluzole, that Biohaven is trying to get approved?Added By: slingshot_insights
What percent of your patients have trouble swallowing tablets or liquids? Is it more than 80%, as Biohaven cites?Added By: slingshot_insights
How likely would you be to switch your patients to Biohaven’s formulation of riluzole, if approved?Added By: slingshot_insights
In its bioequivalence trials, Biohaven showed that sublingual administration of BHV-0223 (40 mg) achieved similar blood exposures to orally ingested Rilutek (50 mg). Is the lower dosage to achieve same results also an advantage here?Added By: slingshot_insights
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.